HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain
- 8 December 2010
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 60 (4) , 626-632
- https://doi.org/10.1016/j.neuropharm.2010.11.026
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedureNeuropharmacology, 2010
- Neural bases for addictive properties of benzodiazepinesNature, 2010
- Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at α1 and α2/3 SubtypesThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Pharmacology and treatment of neuropathic painsCurrent Opinion in Neurology, 2009
- Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targetsTrends in Pharmacological Sciences, 2009
- Antiseizure Activity of Novel γ-Aminobutyric Acid (A) Receptor Subtype-Selective Benzodiazepine Analogues in Mice and Rat ModelsJournal of Medicinal Chemistry, 2009
- Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyondPharmacology Biochemistry and Behavior, 2008
- High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiologyNature Reviews Drug Discovery, 2008
- Spinal prostaglandin E receptors of the EP2 subtype and the glycine receptor α3 subunit, which mediate central inflammatory hyperalgesia, do not contribute to pain after peripheral nerve injury or formalin injectionPain, 2006
- A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in manPain, 1988